Evolus (EOLS) has a debt-to-equity ratio of -5.33, below the Healthcare sector average of 0.27.
Get informed when a big investor buys or sells
+ Follow-5.33
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
Evolus (EOLS) currently reports a debt-to-equity ratio of -5.33. That is below the Healthcare sector average of 0.27. Use the charts on this page to explore Evolus's debt-to-equity ratio history and peer comparisons.
Evolus's debt-to-equity ratio of -5.33 is lower than the Healthcare sector average of 0.27. That is roughly 2110.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The debt-to-equity ratio is a valuation multiple that relates Evolus's market price to a fundamental measure such as earnings, sales, or book value. At -5.33, EOLS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current debt-to-equity ratio of -5.33, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.27. From there, open related valuation or income-statement pages for Evolus, and consider following EOLS for alerts when major investors trade the stock.
Evolus is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -5.33 versus a sector average near 0.27. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EOLS with unrelated industries.